• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FLUOXYMESTERONE Drug Record

  • Summary
  • Interactions
  • Claims
  • FLUOXYMESTERONE chembl:CHEMBL1445 ApprovedAntineoplastic

    Alternate Names:

    FLUOXIMESTERONE
    NSC-10704
    ORA-TESTRYL
    NSC-12165
    FLUOXYMESTERONE CIII
    FLUOXYMESTERONE
    ANDROID-F
    ANDROXY
    HALOTESTIN
    11BETA,17BETA-DIHYDROXY-9ALPHA-FLUORO-17ALPHA-METHYL-4-ANDROSTER-3-ONE
    TESTOSTERONE, 9-FLUORO-11BETA-HYDROXY-17-METHYL-
    9ALPHA-FLUORO-11BETA-HYDROXY-17-METHYLTESTOSTERONE
    17ALPHA-METHYL-9ALPHA-FLUORO-11BETA-HYDROXYTESTERONE
    HALOTESTIN®
    9-FLUORO-11BETA,17BETA-DIHYDROXY-17-METHYLANDROST-4-EN-3-ONE
    17Α-METHYL-9Α-FLUORO-11Β-HYDROXYTESTERONE
    FLUOXIMESTERONA
    FLUOXYMESTERONUM
    chemidplus:76-43-7
    rxcui:4494
    pubchem.compound:6446
    chembl:CHEMBL1445
    drugbank:01185

    Drug Info:

    FDA Approval 1956
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    Drug Indications Anabolic Agents
    Year of Approval 1956
    Drug Class antineoplastic agents
    Drug Class anabolic agents
    (3 More Sources)

    Publications:

    Miner et al., 2007, An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate., Endocrinology
    Kasperk et al., 1989, Androgens directly stimulate proliferation of bone cells in vitro., Endocrinology
    Kemppainen et al., 1999, Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone., Mol. Endocrinol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Fernández et al., 1994, Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes., Endocrinology
    Smallridge et al., 1984, Androgen receptor abnormalities in identical twins with oligospermia. Clinical and biochemical studies., Am. J. Med.
    Mayer et al., 1975, Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol., Am. J. Physiol.
    Morley et al., 1981, The relationship of androgen to the thyrotropin and prolactin responses to thyrotropin-releasing hormone in hypogonadal and normal men., J. Clin. Endocrinol. Metab.
  • FLUOXYMESTERONE   PRL

    Interaction Score: 1.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6161941


    Sources:
    NCI

  • FLUOXYMESTERONE   NR3C1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    173192


    Sources:
    DTC

  • FLUOXYMESTERONE   AR

    Interaction Score: 0.26

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Androgen Receptor agonist

    PMIDs:
    17023534 2521824 10077001 11752352 8119180 6439037


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND TTD

  • TEND: FLUOXYMESTERONE

    • Version: 01-August-2011

    Alternate Names:
    FLUOXYMESTERONE Primary Drug Name

    Drug Info:
    Drug Class anabolic agents
    Drug Class antineoplastic agents
    Year of Approval 1956

    Publications:

  • TdgClinicalTrial: FLUOXYMESTERONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anabolic Agents
    Drug Indications Antineoplastic Agents
    Drug Class small molecule

    Publications:

  • NCI: FLUOXYMESTERONE

    • Version: 14-September-2017

    Alternate Names:
    C507 NCI drug code

    Drug Info:

    Publications:
    Morley et al., 1981, The relationship of androgen to the thyrotropin and prolactin responses to thyrotropin-releasing hormone in hypogonadal and normal men., J. Clin. Endocrinol. Metab.

  • DTC: FLUOXYMESTERONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1445 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Fluoxymesterone

    • Version: 2020.06.01

    Alternate Names:
    D0L2LS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1445

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1445

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21